Skip to content
Gleevec, Glivec(imatinib)
Gleevec, Glivec (imatinib) is a small molecule pharmaceutical. Imatinib was first approved as Gleevec on 2001-05-10. It is used to treat dermatofibrosarcoma, hypereosinophilic syndrome, lymphoid leukemia, myelodysplastic-myeloproliferative diseases, and myeloid leukemia amongst others in the USA. It has been approved in Europe to treat BCR-ABL positive chronic myelogenous leukemia, dermatofibrosarcoma, gastrointestinal stromal tumors, hypereosinophilic syndrome, and myelodysplastic-myeloproliferative diseases amongst others. It is known to target tyrosine-protein kinase ABL1.
Download report
Favorite
Novartis Pharmaceuticals
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
hemic and lymphatic diseasesD006425
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Gleevec (generic drugs available since 2015-12-03)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Imatinib mesylate
Tradename
Company
Number
Date
Products
GLEEVECNovartisN-021588 RX2003-04-18
2 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
gleevecNew Drug Application2020-10-23
imatinib mesylateANDA2023-04-04
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
dermatofibrosarcoma—D018223—
hypereosinophilic syndromeEFO_1001467D017681D72.11
lymphoid leukemia—D007945C91
myelodysplastic-myeloproliferative diseases—D054437—
myeloid leukemia—D007951C92
systemic mastocytosis—D034721C96.21
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01E: Protein kinase inhibitors, antineoplastic and immunomodulating agents
— L01EA: Bcr-abl tyrosine kinase inhibitors
— L01EA01: Imatinib
HCPCS
Code
Description
S0088
Imatinib, 100 mg
Clinical
Clinical Trials
501 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_0000340194923816108
Gastrointestinal stromal tumorsD046152EFO_0000505C49.A1635183671
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.062072133
Breast neoplasmsD001943EFO_0003869C5025—119
Covid-19D000086382U07.1—331—7
Hematologic neoplasmsD0193372——1—3
Systemic mastocytosisD034721C96.21—1—1—2
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938C9514328—148
Myeloid leukemia chronic-phaseD0154665135—426
SarcomaD0125093103——13
Philadelphia chromosomeD010677281—110
GlioblastomaD005909EFO_0000515241——7
Pulmonary arterial hypertensionD000081029—25——6
Graft vs host diseaseD006086D89.81131——5
Myeloid leukemiaD007951C92—12——3
PneumoniaD011014EFO_0003106J18—11——2
Hematologic diseasesD006402EFO_0005803D75.9—11——2
Show 11 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C801012———20
MelanomaD008545411———12
Prostatic neoplasmsD011471C6147———10
Myelomonocytic leukemia chronicD015477C93.124——17
Lung neoplasmsD008175C34.9025———7
Central nervous system neoplasmsD01654354———7
Hypereosinophilic syndromeD017681EFO_1001467D72.11—6——17
Systemic sclerodermaD012595EFO_0000717M3427———7
Ovarian neoplasmsD010051EFO_0003893C5616———6
Myeloid leukemia acuteD015470C92.033———5
Show 88 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—10————10
Multiple myelomaD009101C90.02————2
Hodgkin diseaseD006689C812————2
Leukemia myeloid chronic atypical bcr-abl negativeD054438C92.22————2
Castration-resistant prostatic neoplasmsD0641291————1
AnemiaD000740EFO_0004272D64.91————1
ThrombocytosisD013922D75.831————1
Papillary thyroid cancerD0000772731————1
Acute lung injuryD055371EFO_00046101————1
Choroidal neovascularizationD0202561————1
Show 17 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Gastrointestinal neoplasmsD005770C26.9————11
MastocytosisD008415D47.09————11
Triple negative breast neoplasmsD064726————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameIMATINIB
INNimatinib
Description
Imatinib is a benzamide obtained by formal condensation of the carboxy group of 4-[(4-methylpiperazin-1-yl)methyl]benzoic acid with the primary aromatic amino group of 4-methyl-N(3)-[4-(pyridin-3-yl)pyrimidin-2-yl]benzene-1,3-diamine. Used (as its mesylate salt) for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours. It has a role as an apoptosis inducer, a tyrosine kinase inhibitor and an antineoplastic agent. It is a N-methylpiperazine, a member of pyridines, a member of benzamides, an aromatic amine and a member of pyrimidines. It is functionally related to a benzamide.
Classification
Small molecule
Drug classtyrosine kinase inhibitors
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1
Identifiers
PDB3K5V
CAS-ID152459-95-5
RxCUI282388
ChEMBL IDCHEMBL941
ChEBI ID45783
PubChem CID5291
DrugBankDB00619
UNII IDBKJ8M8G5HI (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
ABL1
ABL1
Organism
Homo sapiens
Gene name
ABL1
Gene synonyms
ABL, JTK7
NCBI Gene ID
25
Protein name
tyrosine-protein kinase ABL1
Protein synonyms
Abelson murine leukemia viral oncogene homolog 1, Abelson tyrosine-protein kinase 1, ABL protooncogene 1 nonreceptor tyrosine kinase, BCR-ABL1 p190, BCR/ABL e8a2 fusion, BCR/ABL1 e1a2 fusion protein, bcr/c-abl oncogene protein, c-abl oncogene 1, receptor tyrosine kinase, p150, Proto-oncogene c-Abl, proto-oncogene tyrosine-protein kinase ABL1, v-abl Abelson murine leukemia viral oncogene homolog 1
Uniprot ID
Q45F09
Mouse ortholog
Abl1 (11350)
tyrosine-protein kinase ABL1 (P00520)
Variants
Clinical Variant
No data
Financial
Gleevec - Novartis
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 43,921 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
6,326 adverse events reported
View more details